Health Technology Assessment in Australia - PHAR9114
Faculty: Faculty of Medicine
School: School of Medical Sciences
Course Outline: https://med.unsw.edu.au/pharmaceutical-medicine
Campus: Sydney
Career: Postgraduate
Units of Credit: 6
EFTSL: 0.12500 (more info)
Indicative Contact Hours per Week: 10
CSS Contribution Charge: 2 (more info)
Tuition Fee: See Tuition Fee Schedule
Further Information: See Class Timetable
View course information for previous years.
Description
PLEASE NOTE: This course has had a change of code and title - up to and including 2009, the course code was PHPH9114. Up to and including 2016, the course title was Pharmacoeconomics.
Health Technology Assessment focusses on the cost-benefit analysis of therapeutic interventions and the role of evidence-based medicine in determining the benefits of these interventions in health management. This course introduces students to the requirements for cost effectiveness for therapeutics and the role of evidence-based medicine in the decision-making process for these products. It covers pricing considerations for ensuring successful applications to the Pharmaceutical Benefits Advisory Committee (PBAC) for entry of medicines on the Pharmaceutical Benefits Scheme (PBS) in Australia. Students will also discuss the different economic methodologies used to determine the cost-benefit analysis of a medicine and when these different methodologies should be used.
Note: This course is one of two options for the compulsory Health Economics component for programmes 5371 and 9370.
Health Technology Assessment focusses on the cost-benefit analysis of therapeutic interventions and the role of evidence-based medicine in determining the benefits of these interventions in health management. This course introduces students to the requirements for cost effectiveness for therapeutics and the role of evidence-based medicine in the decision-making process for these products. It covers pricing considerations for ensuring successful applications to the Pharmaceutical Benefits Advisory Committee (PBAC) for entry of medicines on the Pharmaceutical Benefits Scheme (PBS) in Australia. Students will also discuss the different economic methodologies used to determine the cost-benefit analysis of a medicine and when these different methodologies should be used.
Note: This course is one of two options for the compulsory Health Economics component for programmes 5371 and 9370.
Study Levels
UNSW Quick Links
